T-1101 capsule approved by the TFDA to start Phase I clinical study

Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved by FDA in Nov, 2020 and further by TFDA in Dec, 2020. T-1101: T-1101 Phase I trial is the first-in-human study conducted to evaluate the safety and tolerability of T-1101 …

T-1101 capsule approved by the TFDA to start Phase I clinical study Read More »